Medesis Pharma (France) Performance
| ALMDP Stock | EUR 0.35 0.01 2.94% |
The company secures a Beta (Market Risk) of -1.32, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Medesis Pharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Medesis Pharma is expected to outperform it. At this point, Medesis Pharma SA has a negative expected return of -0.49%. Please make sure to verify Medesis Pharma's jensen alpha, as well as the relationship between the skewness and day median price , to decide if Medesis Pharma SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medesis Pharma SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Medesis |
Medesis Pharma Relative Risk vs. Return Landscape
If you would invest 54.00 in Medesis Pharma SA on September 14, 2024 and sell it today you would lose (19.00) from holding Medesis Pharma SA or give up 35.19% of portfolio value over 90 days. Medesis Pharma SA is generating negative expected returns and assumes 6.1248% volatility on return distribution over the 90 days horizon. Simply put, 54% of stocks are less volatile than Medesis, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medesis Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medesis Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medesis Pharma SA, and traders can use it to determine the average amount a Medesis Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0805
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALMDP |
Estimated Market Risk
| 6.12 actual daily | 54 54% of assets are less volatile |
Expected Return
| -0.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medesis Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medesis Pharma by adding Medesis Pharma to a well-diversified portfolio.
Medesis Pharma Fundamentals Growth
Medesis Stock prices reflect investors' perceptions of the future prospects and financial health of Medesis Pharma, and Medesis Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medesis Stock performance.
| Current Valuation | 8.67 M | |||
| Shares Outstanding | 4.39 M | |||
| Price To Book | 74.91 X | |||
| Price To Sales | 189.31 X | |||
| Revenue | 95.73 K | |||
| EBITDA | (3.05 M) | |||
| Cash And Equivalents | 2.89 M | |||
| Total Debt | 1.28 M | |||
| Earnings Per Share | (0.74) X | |||
| Total Asset | 4.33 M | |||
About Medesis Pharma Performance
Assessing Medesis Pharma's fundamental ratios provides investors with valuable insights into Medesis Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Medesis Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Medesis Pharma SA, a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. The company was founded in 2003 and is based in Montpellier, France. MEDESIS PHARMA is traded on Paris Stock Exchange in France.Things to note about Medesis Pharma SA performance evaluation
Checking the ongoing alerts about Medesis Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medesis Pharma SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medesis Pharma SA generated a negative expected return over the last 90 days | |
| Medesis Pharma SA has high historical volatility and very poor performance | |
| Medesis Pharma SA has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 95.73 K. Net Loss for the year was (2.65 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| About 17.0% of the company shares are held by company insiders |
- Analyzing Medesis Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medesis Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Medesis Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medesis Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medesis Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medesis Pharma's stock. These opinions can provide insight into Medesis Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Medesis Stock Analysis
When running Medesis Pharma's price analysis, check to measure Medesis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medesis Pharma is operating at the current time. Most of Medesis Pharma's value examination focuses on studying past and present price action to predict the probability of Medesis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medesis Pharma's price. Additionally, you may evaluate how the addition of Medesis Pharma to your portfolios can decrease your overall portfolio volatility.